ID

13768

Beschrijving

A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT01433250

Link

https://clinicaltrials.gov/show/NCT01433250

Trefwoorden

Versies (2)
  1. 06-03-16 06-03-16 -
  2. 20-09-21 20-09-21 -
Geüploaded op

6 maart 2016

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Multiple Sclerosis NCT01433250

Engels

Eligibility Multiple Sclerosis NCT01433250

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. was exposed to ain457 or placebo in study cain457b2201 and completed the cain457b2201 study, up to at and including visit 10 (week 24).
Beschrijving

ain457; placebo

Datatype

boolean

Alias
UMLS CUI [1]
C3179548
UMLS CUI [2]
C1696465
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. have been treated with:
Beschrijving

therapy

Datatype

boolean

Alias
UMLS CUI [1]
C0087111
immunosuppressive medications such as azathioprine or methotrexate within 1 month prior to enrollment, if lymphocyte count normal.
Beschrijving

Immunosuppressive Agents; azathioprine; methotrexate

Datatype

boolean

Alias
UMLS CUI [1]
C0021081
UMLS CUI [2]
C0004482
UMLS CUI [3]
C0025677
immunoglobulins and/or monoclonal antibodies (with the exception of ain457) within 2 month prior to enrollment, or if the immunosuppressive effects are likely to persist at enrollment (such as presence of b cell depletion after rituximab treatment).
Beschrijving

immunoglobulins; monoclonal antibodies; b lymphocyte depletion therapy; rituximab

Datatype

boolean

Alias
UMLS CUI [1]
C0021027
UMLS CUI [2]
C0003250
UMLS CUI [3]
C1171324
UMLS CUI [4]
C0393022
2. have received total lymphoid irradiation, bone marrow transplantation, alemtuzumab, cladribine, cyclophosphamide, mitoxantrone or other immunosuppressive treatments with long-lasting (over 6 months) or permanent effects.
Beschrijving

Lymphatic Irradiation; alemtuzumab; cladribine; cyclophosphamide; mitoxantrone

Datatype

boolean

Alias
UMLS CUI [1]
C0024230
UMLS CUI [2]
C0383429
UMLS CUI [3]
C0092801
UMLS CUI [4]
C0010583
UMLS CUI [5]
C0026259
3. have received any live or live attenuated vaccines (including live vaccines for varicella-zoster virus or measles) within 2 months prior to enrollment.
Beschrijving

Vaccines, Attenuated; measles vaccines ; Varicella-zoster vaccine

Datatype

boolean

Alias
UMLS CUI [1]
C0042211
UMLS CUI [2]
C2064743
UMLS CUI [3]
C1319755
4. a diagnosis of chronic disease of the immune system other than ms, or of an immunodeficiency syndrome.
Beschrijving

Chronic disease of immune system; immunodeficiency syndrome

Datatype

boolean

Alias
UMLS CUI [1]
C1290894
UMLS CUI [2]
C0021051
5. current severe depression.
Beschrijving

severe depression

Datatype

boolean

Alias
UMLS CUI [1]
C0588008
6. pregnant or nursing (lactating) women.
Beschrijving

pregnancy; lactating

Datatype

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
7. malignancy diagnosed since enrollment in the core study (except for successfully-treated basal or squamous cell carcinoma of skin).
Beschrijving

malignancy; squamous cell carcinoma of skin

Datatype

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2]
C0553723
8. a new diagnosis of diabetes
Beschrijving

diabetes

Datatype

boolean

Alias
UMLS CUI [1]
C0011849
9. positive testing for tuberculosis (quantiferon or chest x-ray).
Beschrijving

tuberculosis test

Datatype

boolean

Alias
UMLS CUI [1]
C2242734
10. subjects with clinically significant cardiac abnormalities
Beschrijving

cardiac abnormalities

Datatype

boolean

Alias
UMLS CUI [1]
C0018798
11. unable or unwilling to undergo multiple venipunctures
Beschrijving

venipunctures

Datatype

boolean

Alias
UMLS CUI [1]
C0600406
12. unable to undergo mri scans due to newly acquired claustrophobia or metallic implants incompatible with mri.
Beschrijving

mri; claustrophobia ; metallic implant

Datatype

boolean

Alias
UMLS CUI [1]
C0024485
UMLS CUI [2]
C0008909
UMLS CUI [3]
C3693688
other protocol-defined inclusion/exclusion criteria may apply
Beschrijving

inclusion; exclusion criteria

Datatype

boolean

Alias
UMLS CUI [1]
C1512693
UMLS CUI [2]
C0680251
Terug naar het begin van de pagina

Similar models

Eligibility Multiple Sclerosis NCT01433250

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
ain457; placebo
Item
1. was exposed to ain457 or placebo in study cain457b2201 and completed the cain457b2201 study, up to at and including visit 10 (week 24).
boolean
C3179548 (UMLS CUI [1])
C1696465 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
therapy
Item
1. have been treated with:
boolean
C0087111 (UMLS CUI [1])
Immunosuppressive Agents; azathioprine; methotrexate
Item
immunosuppressive medications such as azathioprine or methotrexate within 1 month prior to enrollment, if lymphocyte count normal.
boolean
C0021081 (UMLS CUI [1])
C0004482 (UMLS CUI [2])
C0025677 (UMLS CUI [3])
immunoglobulins; monoclonal antibodies; b lymphocyte depletion therapy; rituximab
Item
immunoglobulins and/or monoclonal antibodies (with the exception of ain457) within 2 month prior to enrollment, or if the immunosuppressive effects are likely to persist at enrollment (such as presence of b cell depletion after rituximab treatment).
boolean
C0021027 (UMLS CUI [1])
C0003250 (UMLS CUI [2])
C1171324 (UMLS CUI [3])
C0393022 (UMLS CUI [4])
Lymphatic Irradiation; alemtuzumab; cladribine; cyclophosphamide; mitoxantrone
Item
2. have received total lymphoid irradiation, bone marrow transplantation, alemtuzumab, cladribine, cyclophosphamide, mitoxantrone or other immunosuppressive treatments with long-lasting (over 6 months) or permanent effects.
boolean
C0024230 (UMLS CUI [1])
C0383429 (UMLS CUI [2])
C0092801 (UMLS CUI [3])
C0010583 (UMLS CUI [4])
C0026259 (UMLS CUI [5])
Vaccines, Attenuated; measles vaccines ; Varicella-zoster vaccine
Item
3. have received any live or live attenuated vaccines (including live vaccines for varicella-zoster virus or measles) within 2 months prior to enrollment.
boolean
C0042211 (UMLS CUI [1])
C2064743 (UMLS CUI [2])
C1319755 (UMLS CUI [3])
Chronic disease of immune system; immunodeficiency syndrome
Item
4. a diagnosis of chronic disease of the immune system other than ms, or of an immunodeficiency syndrome.
boolean
C1290894 (UMLS CUI [1])
C0021051 (UMLS CUI [2])
severe depression
Item
5. current severe depression.
boolean
C0588008 (UMLS CUI [1])
pregnancy; lactating
Item
6. pregnant or nursing (lactating) women.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
malignancy; squamous cell carcinoma of skin
Item
7. malignancy diagnosed since enrollment in the core study (except for successfully-treated basal or squamous cell carcinoma of skin).
boolean
C0006826 (UMLS CUI [1])
C0553723 (UMLS CUI [2])
diabetes
Item
8. a new diagnosis of diabetes
boolean
C0011849 (UMLS CUI [1])
tuberculosis test
Item
9. positive testing for tuberculosis (quantiferon or chest x-ray).
boolean
C2242734 (UMLS CUI [1])
cardiac abnormalities
Item
10. subjects with clinically significant cardiac abnormalities
boolean
C0018798 (UMLS CUI [1])
venipunctures
Item
11. unable or unwilling to undergo multiple venipunctures
boolean
C0600406 (UMLS CUI [1])
mri; claustrophobia ; metallic implant
Item
12. unable to undergo mri scans due to newly acquired claustrophobia or metallic implants incompatible with mri.
boolean
C0024485 (UMLS CUI [1])
C0008909 (UMLS CUI [2])
C3693688 (UMLS CUI [3])
inclusion; exclusion criteria
Item
other protocol-defined inclusion/exclusion criteria may apply
boolean
C1512693 (UMLS CUI [1])
C0680251 (UMLS CUI [2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial